BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21846324)

  • 1. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap).
    Mo SL; Liu WF; Chen Y; Luo HB; Sun LB; Chen XW; Zhou ZW; Sneed KB; Li CG; Du YM; Liang J; Zhou SF
    Comb Chem High Throughput Screen; 2012 Jan; 15(1):36-80. PubMed ID: 21846324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
    Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
    Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6.
    de Graaf C; Oostenbrink C; Keizers PH; van Vugt-Lussenburg BM; van Waterschoot RA; Tschirret-Guth RA; Commandeur JN; Vermeulen NP
    Curr Drug Metab; 2007 Jan; 8(1):59-77. PubMed ID: 17266524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
    Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
    Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6.
    Martiny VY; Carbonell P; Chevillard F; Moroy G; Nicot AB; Vayer P; Villoutreix BO; Miteva MA
    Bioinformatics; 2015 Dec; 31(24):3930-7. PubMed ID: 26315915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
    Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combinatorial approach for the discovery of cytochrome P450 2D6 inhibitors from nature.
    Hochleitner J; Akram M; Ueberall M; Davis RA; Waltenberger B; Stuppner H; Sturm S; Ueberall F; Gostner JM; Schuster D
    Sci Rep; 2017 Aug; 7(1):8071. PubMed ID: 28808272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.
    Zhou SF; Liu JP; Lai XS
    Curr Med Chem; 2009; 16(21):2661-805. PubMed ID: 19601803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling chemical interaction profiles: I. Spectral data-activity relationship and structure-activity relationship models for inhibitors and non-inhibitors of cytochrome P450 CYP3A4 and CYP2D6 isozymes.
    McPhail B; Tie Y; Hong H; Pearce BA; Schnackenberg LK; Ge W; Valerio LG; Fuscoe JC; Tong W; Buzatu DA; Wilkes JG; Fowler BA; Demchuk E; Beger RD
    Molecules; 2012 Mar; 17(3):3383-406. PubMed ID: 22421792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of comparability of Coptis chinensis and Scutellaria baicalensis on five sub-enzymatic activities of liver microsomes in rats].
    Wei LY; Zhang YJ; Wei BH; Ye J; Yang XY; Sun GX
    Zhongguo Zhong Yao Za Zhi; 2013 May; 38(9):1426-9. PubMed ID: 23944082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
    Guengerich FP; Hanna IH; Martin MV; Gillam EM
    Biochemistry; 2003 Feb; 42(5):1245-53. PubMed ID: 12564927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.
    Guengerich FP; Miller GP; Hanna IH; Martin MV; Léger S; Black C; Chauret N; Silva JM; Trimble LA; Yergey JA; Nicoll-Griffith DA
    Biochemistry; 2002 Sep; 41(36):11025-34. PubMed ID: 12206675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
    Venhorst J; ter Laak AM; Commandeur JN; Funae Y; Hiroi T; Vermeulen NP
    J Med Chem; 2003 Jan; 46(1):74-86. PubMed ID: 12502361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions.
    Lewis DF; Dickins M; Lake BG; Goldfarb PS
    Drug Metabol Drug Interact; 2003; 19(3):189-210. PubMed ID: 14682610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
    Wang A; Stout CD; Zhang Q; Johnson EF
    J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of drug metabolism: the case of cytochrome P450 2D6.
    Vermeulen NP
    Curr Top Med Chem; 2003; 3(11):1227-39. PubMed ID: 12769702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing QSAR models for predicting ligand binding to the drug-metabolizing cytochrome P450 isoenzyme CYP2D6.
    Saraceno M; Massarelli I; Imbriani M; James TL; Bianucci AM
    Chem Biol Drug Des; 2011 Aug; 78(2):236-51. PubMed ID: 21575140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators.
    Livezey M; Nagy LD; Diffenderfer LE; Arthur EJ; Hsi DJ; Holton JM; Furge LL
    Drug Metab Lett; 2012 Mar; 6(1):7-14. PubMed ID: 22372551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
    Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
    J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.